RBDCOV, an innovative and competitive solution against COVID-19

HERA, Health Emergency Preparedness and Response Authorit signs Joint Procurement contract with HIPRA for COVID-19 vaccines.

The RBDCOV project represents a decisive step forward against the COVID-19 supplying its recombinant protein vaccine, a more competitive solution

HIPRA’s COVID-19 vaccine has been developed as a booster dose in children, adolescents and immunocompromised patients. Due to an increasing number of cases in Europe, and the difficulty of middle and low income countries to access vaccination of the population, HIPRA’s vaccine will help to strenghten the European Health structure. 

The signing of the framework contract allows the vaccine being marketed as soon as it has received a positive evaluation by the EMA, the European Medicines Agency. This approval is expected to be effective for the autumn booster.  

Stella Kyriakides, Commissioner for Health and Food Safety, said: “The HIPRA vaccine adds yet another option to complement our broad vaccine portfolio for our Member States and citizens. An increase in vaccination and boosting is essential over the coming months. We are working tirelessly to make sure there are vaccines available for all. This is our European Health Union in action – preparing ahead and being ready to act.” 

HIPRA vaccine using the recombinant protein can be stored at refrigerated temperature between 2 and 8ºC, facilitating storage and distribution in Europe and across the world, and reducing costs. 

The development of the vaccine is based on already known technologies and used in the treatment of other diseases, making it a particularly safe option.